Korva is a scroll of the internet’s best ideas.
14% higher mortality with penicillin label
The study compared the long-term outcomes of 60,000 patients with a penicillin allergy in their record against more than 200,000 patients without one. It was a nicely controlled observational study.
Taking penicillin spares a patient several things: antibiotic resistance, C. diff colitis, overly long hospital stays, and surgical infections if an operation is needed. It also avoids the side effects of a more toxic antibiotic, which by its nature can cause more renal failure or more diarrhea.
Picture two people with strep throat. The one without the label gets penicillin, the indicated drug, and the strep goes away with no long-term effects at a low cost. The one with the label gets a Z-pack, which does not fully clear it, then calls back and gets a bigger antibiotic that causes some other problem. A tonsil abscess is possible, and so is an unnecessary quinolone such as ciprofloxacin.
Why do people with allergy labels die more often?
Observational studies cannot prove cause, but researchers point to the antibiotics these patients receive instead of penicillin. Substitutes like vancomycin, clindamycin, and fluoroquinolones are linked to more infection recurrences and more complications. Patients with a label also tend to have more health problems and more hospital contact. Untangling those factors is why the study's controls mattered.
Why do broader antibiotics drive resistance?
Narrow-spectrum drugs like penicillin kill a limited range of bacteria. Broad-spectrum drugs hit many species at once, including harmless gut bacteria, which leaves survivors free to multiply. Each exposure gives bacteria another chance to pick up or select for resistance genes. This is why public health agencies, including the World Health Organization, urge matching the narrowest effective drug to the infection.
Why can a Z-pack fail to clear strep?
Azithromycin, the drug in a Z-pack, is a macrolide, and macrolide resistance among group A strep has been documented in many countries. In the United States, surveillance by the Centers for Disease Control and Prevention has reported meaningful rates of macrolide-resistant strains. Penicillin has remained reliable against group A strep for decades, since no penicillin-resistant strains have been confirmed. That makes it the standard first-line drug for strep throat.
More from Freakonomics Radio Network
